AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance with scheduling of assigned treatments
Number of subjects: 0
Study 36823955 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Shock Absorber (ISA)
Number of subjects: 0
Study 36823955 — intervention group
Group type: COMPARATOR
Intervention: High Tibial Osteotomy (HTO)
Number of subjects: 0
Study 36824039 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping exergame training for 12 weeks
Number of subjects: 18
Study 36824039 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise (active control group) for 12 weeks
Number of subjects: 18
Study 36824050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Health and Financial Incentives
Number of subjects: 0
Study 36824050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36824052 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1% (n = 18)
Number of subjects: 36
Study 36824052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% (n = 18)
Number of subjects: 36
Study 36824052 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 36
Study 36824052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 36
Study 36824387 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT) at 800 nm
Number of subjects: 10
Study 36824456 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived cells (BMC), 100 million cells injected during CABG surgery
Number of subjects: 143
Study 36824456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 143
Study 36824611 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSPII score system applied before treatment
Number of subjects: 231
Study 36824611 — intervention group
Group type: COMPARATOR
Intervention: SPSP score
Number of subjects: 231
Study 36824611 — intervention group
Group type: COMPARATOR
Intervention: Disease severity scores (DSS)
Number of subjects: 231
Study 36824650 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Transplantation (LT)
Number of subjects: 215
Study 36824650 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Transplantation (RT)
Number of subjects: 215
Study 36824650 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids use
Number of subjects: 215
Study 36824650 — intervention group
Group type: COMPARATOR
Intervention: Acute events (graft rejection and infection)
Number of subjects: 215
Study 36824650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective follow-up (pDIABGRAFT)
Number of subjects: 215
Study 36824785 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ practice
Number of subjects: 32
Study 36824785 — intervention group
Group type: EXPERIMENTAL
Intervention: P.Volve low-intensity exercises
Number of subjects: 32
Study 36824785 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n=28)
Number of subjects: 32
Study 36824823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transspinal stimulation
Number of subjects: 45
Study 36824823 — intervention group
Group type: COMPARATOR
Intervention: Sham transspinal stimulation
Number of subjects: 45
Study 36824884 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention for medication assisted treatment
Number of subjects: 0
Study 36824884 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 36824929 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Forest Qigong™ intervention practiced at least 3 times per week for 12 weeks, using an online video combining movement with kinesthetic imagery.
Number of subjects: 23
Study 36825238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue image-based diagnostic model
Number of subjects: 937
Study 36825238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue coating microbiome-based model using genus data
Number of subjects: 937
Study 36825238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue coating microbiome-based model using species data
Number of subjects: 937
Study 36825238 — intervention group
Group type: EXPERIMENTAL
Intervention: Three tongue image-based models
Number of subjects: 937
Study 36825238 — intervention group
Group type: COMPARATOR
Intervention: Combination of eight blood biomarkers
Number of subjects: 937
Study 36825252 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO case definition
Number of subjects: 263218
Study 36825252 — intervention group
Group type: EXPERIMENTAL
Intervention: UKHSA case definition
Number of subjects: 263218
Study 36825252 — intervention group
Group type: EXPERIMENTAL
Intervention: ECDC case definition
Number of subjects: 263218
Study 36825252 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC case definition
Number of subjects: 263218
Study 36825252 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not meet case definitions
Number of subjects: 263218
Study 36825610 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception threshold tracking
Number of subjects: 80
Study 36825610 — intervention group
Group type: COMPARATOR
Intervention: Corneal confocal microscopy
Number of subjects: 80
Study 36825693 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05212377 (SAM760)
Number of subjects: 0
Study 36825887 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 49
Study 36825887 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exposed infants)
Number of subjects: 49
Study 36825895 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on baseline quality of life, admission type, and Glasgow Coma Scale
Number of subjects: 1804
Study 36825895 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of the prediction model
Number of subjects: 1804
Study 36825929 — intervention group
Group type: COMPARATOR
Intervention: No trauma
Number of subjects: 914
Study 36825929 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental trauma
Number of subjects: 914
Study 36825929 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal trauma
Number of subjects: 914
Study 36825929 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 914
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Module 1: online supervised group-based (M1)
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Module 2: online unsupervised (M2)
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Module 3: in-person supervised (M3)
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Online exercise programs (M1, M2)
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Module 3 (M3)
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise programs
Number of subjects: 92
Study 36826074 — intervention group
Group type: EXPERIMENTAL
Intervention: Online exercise programs
Number of subjects: 92
Study 36826464 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-6876, a CBP/p300 bromodomain inhibitor
Number of subjects: 0
Study 36826476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg on day 1 and day 14)
Number of subjects: 21
Study 36826476 — intervention group
Group type: EXPERIMENTAL
Intervention: [89Zr]-rituximab PET imaging
Number of subjects: 21
Study 36826476 — intervention group
Group type: EXPERIMENTAL
Intervention: [89Zr]-rituximab SUVmean
Number of subjects: 21
Study 36826514 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine dentin-derived graft material (Ivory Dentin Graft™)
Number of subjects: 36
Study 36826514 — intervention group
Group type: COMPARATOR
Intervention: Commercial bone-derived graft material
Number of subjects: 36
Study 36826589 — intervention group
Group type: EXPERIMENTAL
Intervention: Overperforming hospitals
Number of subjects: 3902
Study 36826589 — intervention group
Group type: COMPARATOR
Intervention: Underperforming hospitals
Number of subjects: 3902
Study 36826820 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) and paclitaxel (175 mg/m2) every 3 weeks for 6 cycles (EP regimen)
Number of subjects: 813
Study 36826820 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles followed by paclitaxel (175 mg/m2) every 3 weeks for 4 cycles (EC-P regimen)
Number of subjects: 813
Study 36826820 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel (EP regimen)
Number of subjects: 813
Study 36826820 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide followed by paclitaxel (EC-P regimen)
Number of subjects: 813
Study 36826834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes management (automated insulin delivery system)
Number of subjects: 113
Study 36826834 — intervention group
Group type: COMPARATOR
Intervention: Standard care (continuous glucose monitor)
Number of subjects: 113
Study 36826844 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (n=47)
Number of subjects: 88
Study 36826844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 88
Study 36826976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app plus VR group
Number of subjects: 80
Study 36826976 — intervention group
Group type: COMPARATOR
Intervention: Mobile app-only group
Number of subjects: 80
Study 36826995 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-570 (monoclonal antibody against ICOS) administered intravenously every 3 weeks for up to 12 cycles at doses ranging from 0.01 to 3 mg/kg.
Number of subjects: 23
Study 36826996 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-Source Automated Insulin Delivery AndroidAPS
Number of subjects: 0
Study 36826996 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36827003 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with generalized periodontitis (SGP)
Number of subjects: 80
Study 36827003 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with healthy periodontium (SHP)
Number of subjects: 80
Study 36827003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers with generalized periodontitis (NGP)
Number of subjects: 80
Study 36827003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers with healthy periodontium (NHP)
Number of subjects: 80
Study 36827003 — intervention group
Group type: COMPARATOR
Intervention: Generalized periodontitis groups (SGP, NGP)
Number of subjects: 80
Study 36827003 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 36827018 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium treatment
Number of subjects: 1
Study 36827327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based ART (hbART) consisting of 3 home-visits in a 3-month period by a certified male study nurse ART provider.
Number of subjects: 700
Study 36827327 — intervention group
Group type: COMPARATOR
Intervention: Facility-based ART (fbART) involving counselling at the male participant's home or a nearby preferred location, followed by escort to the local health facility.
Number of subjects: 700
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal antigen Rapid Diagnostic Tests (RDT)
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva RT-PCR
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal (NP) RT-PCR
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Any test (RDT, saliva PCR, NP PCR)
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: STANDARD-Q® Ag test
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Panbio™ Ag test
Number of subjects: 928
Study 36827328 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-VIRO® Ag test
Number of subjects: 928
Study 36827396 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 186
Study 36827396 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-to-lymphocyte ratio (PLR)
Number of subjects: 186
Study 36827396 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Lung cancer Inflammation Index (ALI)
Number of subjects: 186
Study 36827396 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 186
Study 36827440 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention readiness measure (HPRM)
Number of subjects: 315
Study 36827440 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy subscale of HPRM
Number of subjects: 315
Study 36827440 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP disclosure subscale of HPRM
Number of subjects: 315
Study 36827440 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support subscale of HPRM
Number of subjects: 315
Study 36827620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 36827620 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 0
Study 36827715 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated communication materials
Number of subjects: 100
Study 36827750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (UCM)
Number of subjects: 1730
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor STn expression above the median
Number of subjects: 139
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: PLN STn expression
Number of subjects: 139
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor MUC1 expression
Number of subjects: 139
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor MUC4 expression
Number of subjects: 139
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Tn and STn expression
Number of subjects: 139
Study 36827840 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Tn and MUC1 expression
Number of subjects: 139
Study 36827856 — intervention group
Group type: EXPERIMENTAL
Intervention: fALFF in the central executive network (CEN)
Number of subjects: 132
Study 36827856 — intervention group
Group type: COMPARATOR
Intervention: ReHo in the ventral visual pathway (VVP)
Number of subjects: 132
Study 36827856 — intervention group
Group type: COMPARATOR
Intervention: FC in temporal-sensorimotor regions
Number of subjects: 132
Study 36827906 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher objective SLE impact scores over follow-up
Number of subjects: 171
Study 36827906 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE impact scores
Number of subjects: 171
Study 36827906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of change in epigenetic age
Number of subjects: 171
Study 36828030 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 27
Study 36828201 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Number of subjects: 0
Study 36828201 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (TAC) and mycophenolate mofetil (MMF)
Number of subjects: 0
Study 36828283 — intervention group
Group type: EXPERIMENTAL
Intervention: French AmbUlatory Cesarean Section
Number of subjects: 116
Study 36828283 — intervention group
Group type: COMPARATOR
Intervention: Standard cesarean delivery
Number of subjects: 116
Study 36828343 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemic (glycemia 2.2 to 8.3 mmol/L)
Number of subjects: 545
Study 36828343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic (at least 1 measurement <2.2 mmol/L)
Number of subjects: 545
Study 36828343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic (at least 1 measurement >8.3 mmol/L)
Number of subjects: 545
Study 36828343 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic lability (at least 1 episode of hypoglycemia and 1 episode of hyperglycemia)
Number of subjects: 545
Study 36828619 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 351
Study 36828619 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anterior vitrectomy
Number of subjects: 351
Study 36828619 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcornea
Number of subjects: 351
Study 36828619 — intervention group
Group type: EXPERIMENTAL
Intervention: CC family history
Number of subjects: 351
Study 36828643 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 739
Study 36828643 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W)
Number of subjects: 739
Study 36828643 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (Q4W)
Number of subjects: 739
Study 36828643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 36828650 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) intervention
Number of subjects: 157
Study 36828650 — intervention group
Group type: COMPARATOR
Intervention: Home-sent patient information (control group)
Number of subjects: 157
Study 36828654 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine plus high-intensity rosuvastatin in addition to standard of care
Number of subjects: 250
Study 36828654 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 250
Study 36828681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapeutic intervention for indolent ATLL
Number of subjects: 0
Study 36828681 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study 36828719 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20 and QIV coadministration
Number of subjects: 1796
Study 36828719 — intervention group
Group type: COMPARATOR
Intervention: Separate Administration of QIV and PCV20
Number of subjects: 1796
Study 36828828 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36828925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IV) for 6 months
Number of subjects: 70
Study 36828925 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous) for 12 months
Number of subjects: 70
Study 36828925 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PDUS scores
Number of subjects: 70
Study 36828925 — intervention group
Group type: EXPERIMENTAL
Intervention: Other disease assessments (DAS28 and CDAI)
Number of subjects: 70
Study 36828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cysteine intake
Number of subjects: 45
Study 36828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensors eccentric peak torque
Number of subjects: 45
Study 36828945 — intervention group
Group type: EXPERIMENTAL
Intervention: One-repetition maximum in back squat exercise
Number of subjects: 45
Study 36828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione peroxidase (GPx) activity
Number of subjects: 45
Study 36828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle GSSG
Number of subjects: 45
Study 36829104 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg·kg)
Number of subjects: 154
Study 36829104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 36829108 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) with pulse amplitude ratio (PAR) measurement
Number of subjects: 73
Study 36829108 — intervention group
Group type: COMPARATOR
Intervention: Control group (non LHF group)
Number of subjects: 73
Study 36829135 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous graft (AVG)
Number of subjects: 262
Study 36829135 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 262
Study 36829135 — intervention group
Group type: EXPERIMENTAL
Intervention: AVG
Number of subjects: 262
Study 36829135 — intervention group
Group type: COMPARATOR
Intervention: AVF
Number of subjects: 262
Study 36829154 — intervention group
Group type: EXPERIMENTAL
Intervention: Iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily.
Number of subjects: 146
Study 36829179 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus structured diabetes self-management education program
Number of subjects: 22
Study 36829179 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 22
Study 36829237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Together intervention using the Playbook implementation platform
Number of subjects: 400
Study 36829237 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 36829240 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays)
Number of subjects: 60
Study 36829240 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays)
Number of subjects: 60
Study 36830710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidomic analyses of synovial fluids from patients with chronic joint pain
Number of subjects: 0
Study 36830710 — intervention group
Group type: COMPARATOR
Intervention: Lipid levels in synovial fluid
Number of subjects: 0
Study 36830710 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC16:0 levels
Number of subjects: 0
Study 36830710 — intervention group
Group type: EXPERIMENTAL
Intervention: Other choline-containing lipids
Number of subjects: 0
Study 36830710 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lipid species in synovial fluid
Number of subjects: 0
Study 36830825 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses of 70 to 105 Gy delivered in a single fraction.
Number of subjects: 23
Study 36830825 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses equal to or less than 85 Gy.
Number of subjects: 23
Study 36830825 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses of 95 and 100 Gy.
Number of subjects: 23
Study 36830825 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless CyberKnife SRS, doses below 90 Gy.
Number of subjects: 23